

I. Supplemental Response Enclosing a Corrected Terminal Disclaimer

On November 8, 2006, Applicants submitted an executed Terminal Disclaimer, to obviate the double patenting rejection over prior patent No. 6,688,311. However there were several typographical errors on the Terminal Disclaimer as submitted. Please find attached, as a replacement for the previously submitted document, a Terminal Disclaimer indicating the proper application serial number and inventor name.

Thus, the rejection should be withdrawn.

III. Conclusion

All issues raised in the Office Action have been addressed.  
Reconsideration and allowance of claims 1-21 is requested.

The Commissioner is hereby authorized to charge any fee(s) required, including any Terminal Disclaimer fee under 37 CFR 1.20(d), or necessary for the filing, processing or entering of this paper or any of the enclosed papers and to refund any overpayment to deposit account 01-0885.

Respectfully submitted,

/STEPHEN DONOVAN/

Date: January 29, 2006

\_\_\_\_\_  
Stephen Donovan, Reg. No. 33,433

Address all inquires and correspondence to:

Stephen Donovan  
Allergan, Inc., Legal Department  
2525 Dupont Drive  
Irvine, CA 92612  
Telephone: 714 246 4026  
Fax: 714 246 4249

Attachment: Terminal Disclaimer